Cantor Fitzgerald Comments on InflaRx FY2026 Earnings

InflaRx (NASDAQ:IFRX) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for InflaRx in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings per share of ($0.65) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $10.00 price objective on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Wednesday, May 7th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million.

Several other equities research analysts also recently weighed in on IFRX. Guggenheim raised their price target on shares of InflaRx from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 26th. Oppenheimer reduced their price target on shares of InflaRx from $6.00 to $3.00 and set an “outperform” rating for the company in a research report on Thursday, May 29th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st. Finally, Raymond James downgraded shares of InflaRx from a “strong-buy” rating to an “outperform” rating and set a $2.00 price target for the company. in a research report on Thursday, May 29th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $6.60.

InflaRx Stock Down 0.6%

Shares of IFRX opened at $0.83 on Tuesday. The company has a market capitalization of $55.92 million, a P/E ratio of -0.77 and a beta of 1.29. The firm has a 50 day moving average of $1.28 and a 200 day moving average of $1.76. InflaRx has a twelve month low of $0.71 and a twelve month high of $2.82.

Institutional Investors Weigh In On InflaRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. 683 Capital Management LLC boosted its holdings in InflaRx by 26.8% in the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock worth $2,678,000 after purchasing an additional 555,000 shares during the last quarter. Woodline Partners LP purchased a new stake in InflaRx in the first quarter worth approximately $766,000. Northern Trust Corp boosted its holdings in InflaRx by 1,933.1% in the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock worth $1,647,000 after purchasing an additional 634,045 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in InflaRx in the fourth quarter worth approximately $1,576,000. Finally, DAFNA Capital Management LLC purchased a new stake in InflaRx in the first quarter worth approximately $459,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.